Product Information
XGEVA 120 MG/1.7 ML VIAL is a brand product labeled by Amgen Inc., priced at $2001.5168 per ML under NDC 55513073001. Its NADAC has been published 188 times since Nov 28, 2013.
Strength
120 mg/1.7mL
Manufacturer
Amgen Inc.NDC
55513073001
Classification
Brand
Dosage Form
INJECTION
Route
SUBCUTANEOUS
Effective Date
1/7/2026
Active Ingredients
DENOSUMABApproval Type
Biologic (BLA)
FDA Application
BLA125320On Market Since
11/18/2010
Pharmacological Classes
Price Statistics
The NADAC for XGEVA 120 MG/1.7 ML VIAL has been published 188 times since Nov 28, 2013, and over the history we have for it it has risen 110.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2001.5168 per ML |
|---|---|
| All-time high | $2001.5168 (Sep 30, 2026) |
| All-time low | $950.3678 (Nov 28, 2013) |
| 52-week high | $2001.5168 |
| 52-week low | $1943.2202 |
| Median price | $1002.5059 |
| Average price | $1451.8872 |
| Largest weekly change | +93.8% (Jan 22, 2025) |
| Weeks tracked | 188 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Amgen Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
denosumab market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
RANK Ligand Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of XGEVA 120 MG/1.7 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for XGEVA 120 MG/1.7 ML VIAL, manufactured by Amgen Inc., is $2001.5168 per ML (NDC 55513073001), effective Sep 30, 2026.
How has the price of XGEVA 120 MG/1.7 ML VIAL changed over time?
Over the history we have for it, the NADAC for XGEVA 120 MG/1.7 ML VIAL has risen 110.6%. It has been tracked across 188 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for XGEVA 120 MG/1.7 ML VIAL?
Since Nov 28, 2013, the NADAC for XGEVA 120 MG/1.7 ML VIAL has ranged from a low of $950.3678 (Nov 28, 2013) to a high of $2001.5168 (Sep 30, 2026), with a median of $1002.5059 per ML.
Are there cheaper alternatives to XGEVA 120 MG/1.7 ML VIAL?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as XGEVA 120 MG/1.7 ML VIAL in a comparable dosage form, but none are currently priced below it.
Who manufactures XGEVA 120 MG/1.7 ML VIAL?
XGEVA 120 MG/1.7 ML VIAL (NDC 55513073001) is labeled by Amgen Inc., and CMS classifies it as a brand product.